Overview


Human combination vaccines refer to vaccines that protect against multiple diseases within a single shot. These vaccines are formulated to contain antigens (substances that trigger an immune response) from two or more different pathogens. Combining vaccines reduces the number of shots a person needs to receive. This is particularly important for children, who may receive numerous vaccinations in their early years. Combining vaccines can be more cost-effective than administering each vaccine separately. It saves on the cost of manufacturing, administration, and distribution. Having fewer injections can improve patient compliance, as individual may be more likely to complete their recommended vaccination schedules. There are different types of combination vaccines, including DTaP/IPV/Hep B, DTaP/Hib/IPV, MMR II, and Hep B-Hib.

Human combination vaccines are a crucial tool in modern medicine, effectively safeguarding individuals against multiple diseases with a single shot. These vaccines primarily fall into two categories based on their production process: inactivated and live attenuated vaccines. Inactivated vaccines are made using viruses or bacteria that have been neutralized, rendering them unable to replicate or cause disease. This is typically achieved through chemical or heat treatment. Once administered, the immune system recognizes these inactivated pathogens as foreign invaders, triggering the production of antibodies. Common examples of inactivated vaccines include the polio vaccine and the hepatitis A vaccine. On the other hand, live attenuated vaccines are made from weakened forms of the actual live viruses or bacteria. These weakened versions are often modified to be less harmful, culturing them under conditions that are different from their normal host environment. When administered, live attenuated vaccines stimulate a robust immune response, similar to during a natural infection. This results in the production of long-lasting immunity. Notable examples of live attenuated vaccines include those for measles, mumps, and rubella (MMR).

FutureWise Market Research has published a report that provides an insightful analysis human combination vaccines market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry. According to the analysis conducted by FutureWise research analysts human combination vaccines market estimated to register a considerable growth rate over the forecast period. This report lists the market segments and potential prospects available across this industry, in addition providing crucial information on the total valuation currently held by the industry. Moreover, this report will assist key management individuals in an organisation to enhance their decisions pertaining to business expansion as well as strategic changes for increasing customer base.

  • Sanofi,
  • Pfizer Inc.
  • Cadila Healthcare Ltd.
  • GlaxoSmithKline plc
  • CSL Ltd.
  • Mitsubishi Tanabe Pharma Corp.
  • DAIICHI SANKYO COMPANY, LIMITED
  • Merck & Co.
  • Crunchbase Inc.
  • Mass Biologics
  • Meiji Holdings Co. Ltd
  • Serum Institute of India Moderna
  • Astrazeneca
  • Influvac
  • Biological
  • PaxVax Corporation
  • Emergent BioSolutions Inc
  • CNBG
  • Takeda Pharmaceutical Co. Ltd.
  • NPS MedicineWise.

(Note: The list of the major players will be updated with the latest market scenario and trends)

The rising incidence of antiviral drug resistance is expected to drive the demand for human combination vaccines market growth. As viruses develop resistance to existing treatments, there is a critical need for innovative antiviral drugs to combat evolving strains. This dynamic fuels research and development efforts, spurring pharmaceutical companies and researchers to invest in creating more effective and resilient antiviral therapies. This escalation in demand for next-generation antiviral drugs is projected to catalyze market expansion, addressing the urgent global challenge of combating drug-resistant viral infections. Moreover, technological advancements in vaccine research and development have ushered in a new era of more potent combination vaccines. These advancements allow scientists to efficiently combine multiple antigens, enhancing the immune response and providing broader protection against various diseases in a single shot. This streamlines the vaccination process and bolsters overall efficacy, making combination vaccines an increasingly attractive option for healthcare providers and policymakers seeking to maximize immunization coverage and safeguard public health. Also, the adult vaccination represents an underexplored healthcare frontier, offering manufacturers a significant opportunity to replenish critical gaps. The focus of vaccination efforts has primarily centered on pediatric populations, leaving a substantial portion of the adult demographic underserved. By developing combination vaccines tailored to address prevalent diseases affecting adults, manufacturers stand to tap into a vast and relatively untapped market. This strategic expansion not only addresses a pressing public health need but also holds the potential for substantial growth and revenue generation for forward-thinking pharmaceutical companies. However, the approval process for combination vaccines poses a significant barrier, often more intricate than single-antigen vaccines. This increased complexity may hinder manufacturers, potentially resulting in slower market entry and adoption. Additionally, vaccine hesitancy within certain populations presents a substantial restraint. Misinformation, deeply ingrained cultural beliefs, and apprehensions about potential side effects might lead to reluctance or resistance to adopting combination vaccines. Therefore, hindering the growth of the market during the projection period.

By Product Type

  • Inactivated vaccine
  • Live attenuated vaccine

By Age Group

  • Children
  • Adults

By Combination Type

  • DTaP/IPV/Hep B
  • DTaP/Hib/IPV
  • MMR II
  • Hep B-Hib
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Retailer Pharmacies
  • Online Pharmacies

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

This market research report also emphasis on factors affecting the growth rate in various regions listed above. A deep-down analysis of region will also be provided in the final version of this market which is based on conclusion of primary interviews and secondary data point gathered during the process.

By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. North America registered highest share in the market in 2022. Due to factors such as an increase in the prevalence of infectious diseases, an increase in antiviral drug resistance, and a rise in the pediatric population in the region is expected to drive the market expansion. For instance, as stated in a 2021 review article published in Nature, a scientific journal, the administration of vaccines plays a crucial role in reducing the spread of antimicrobial drug resistance. This is achieved through their targeted action against specific infectious antigens. Additionally, the rising interest of manufacturers in creating novel vaccines to target a broad range of diseases further boosts the growth potential of the human combination vaccine market. Also, various government initiatives and partnerships to create awareness regarding vaccination and provide free or easy access to vaccines further propel the growth of the human combination vaccines market over the forecast period

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Human Combination Vaccines Market By Product Type, By Age Group, By Combination Type, By Distribution Channel, and By Region
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape, mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.  Market Introduction
    •   1. Objectives of the Study 
        2. Market Definition 
        3. Market Scope 
           3.1. Years Considered for the Study
           3.2. Market Covered
        4. Currency 
        5. Limitations 
        6. Stakeholders 

  • 2.  Research Methodology
    •   1 Research Data 
           1.1. Secondary Data
              1.1.1. Key Data from Secondary Sources
           1.2 Primary Data
              1.2.1. Key Data from Primary Sources
        3.Market Size Estimation 
        4. Market Breakdown and Data Triangulation 
        5. Assumptions for the Study 

  • 3.  Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights

  • 4.  Human Combination Vaccines Market Variables, Trends & Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Application Overview
        6. Regulatory Framework
           6.1. Reimbursement Framework
           6.2. Standards and Compliances

  • 5.  Market Overview
    •   1. Market Dynamics
           1.1. Market Driver Analysis
              1.1.1. Increasing focus of Human Combination Vaccines Market Companies on Brand Protection
              1.1.2. Untapped Opportunities in Emerging Regions
           1.2. Market Restraint Analysis
              1.2.1. High Cost Associated with Implementation of Predictive Analysis
           1.3. Industry Challenges
              1.3.1. Presence of Ambiguous Regulatory Framework

  • 6.  Human Combination Vaccines Market Analysis Tools
    •   1. Industry Analysis - Porter’s
           1.1. Supplier Power
           1.2. Buyer Power
           1.3. Substitution Threat
           1.4. Threat from New Entrants
           1.5. Competitive Rivalry
        2. Pestel Analysis
           2.1. Political Landscape
           2.2. Environmental Landscape
           2.3. Social Landscape
           2.4. Application Landscape
           2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
           3.1. Joint Ventures
           3.2. Mergers and Acquisitions
           3.3. Licensing and Partnership
           3.4. Application Collaborations
           3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies

  • 7.  Human Combination Vaccines Market, By Product Type Historical Analysis and Forecast 2023-2031 (USD Million)
      1. Inactivated vaccine
      2. Live attenuated vaccine
  • 8.  Human Combination Vaccines Market, By Age Group Historical Analysis and Forecast 2023-2031 (USD Million)
      1. Children
      2. Adults
  • 9.  Human Combination Vaccines Market, By Combination Type Historical Analysis and Forecast 2023-2031 (USD Million)
      1. DTaP/IPV/Hep B
      2. DTaP/Hib/IPV
      3. MMR II
      4. Hep B-Hib
      5. Others
  • 10.  Human Combination Vaccines Market, By Distribution Channel Historical Analysis and Forecast 2023-2031 (USD Million)
      1. Hospital Pharmacies
      2. Retailer Pharmacies
      3. Online Pharmacies
  • 11.  North America Human Combination Vaccines Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
           2.1. U.S.A
           2.2. Canada
           2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 12.  Latin America Human Combination Vaccines Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
           2.1. Brazil
           2.2. Venezuela
           2.3. Argentina
           2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 13.  Europe Human Combination Vaccines Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
           2.1. Germany
           2.2. U.K
           2.3. France
           2.4. Italy
           2.5. Spain
           2.6. Russia
           2.7. Poland
           2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 14.  Asia Pacific Human Combination Vaccines Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
           2.1. Japan
           2.2. China
           2.3. India
           2.4. Australia and New Zealand
           2.5. ASEAN
           2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031  

  • 15.  Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
           2.1. GCC
           2.2. Israel
           2.3. South Africa
           2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 16.  Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix

  • 17.  Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Sanofi
           1.1. Company Overview
           1.2. Product Portfolio
           1.3. SWOT Analysis
           1.4. Financial Overview
           1.5. Strategic Overview
        2. Pfizer Inc.
           2.1. Company Overview
           2.2. Product Portfolio
           2.3. SWOT Analysis
           2.4. Financial Overview
           2.5. Strategic Overview
        3. Cadila Healthcare Ltd.
           3.1. Company Overview
           3.2. Product Portfolio
           3.3. SWOT Analysis
           3.4. Financial Overview
           3.5. Strategic Overview
        4. GlaxoSmithKline plc
           4.1. Company Overview
           4.2. Product Portfolio
           4.3. SWOT Analysis
           4.4. Financial Overview
           4.5. Strategic Overview
        5. CSL Ltd.
           5.1. Company Overview
           5.2. Product Portfolio
           5.3. SWOT Analysis
           5.4. Financial Overview
           5.5. Strategic Overview
        6. Mitsubishi Tanabe Pharma Corp.
           6.1. Company Overview
           6.2. Product Portfolio
           6.3. SWOT Analysis
           6.4. Financial Overview
           6.5. Strategic Overview
        7. DAIICHI SANKYO COMPANY, LIMITED
           7.1. Company Overview
           7.2. Product Portfolio
           7.3. SWOT Analysis
           7.4. Financial Overview
           7.5. Strategic Overview
        8. Merck & Co.
           8.1. Company Overview
           8.2. Product Portfolio
           8.3. SWOT Analysis
           8.4. Financial Overview
           8.5. Strategic Overview
        9. Crunchbase Inc.
           9.1. Company Overview
           9.2. Product Portfolio
           9.3. SWOT Analysis
           9.4. Financial Overview
           9.5. Strategic Overview
        10. Mass Biologics
           10.1. Company Overview
           10.2. Product Portfolio
           10.3. SWOT Analysis
           10.4. Financial Overview
           10.5. Strategic Overview
        11. Meiji Holdings Co. Ltd
           11.1. Company Overview
           11.2. Product Portfolio
           11.3. SWOT Analysis
           11.4. Financial Overview
           11.5. Strategic Overview
        12. Serum Institute of India Moderna
           12.1. Company Overview
           12.2. Product Portfolio
           12.3. SWOT Analysis
           12.4. Financial Overview
           12.5. Strategic Overview
        13. Astrazeneca
           13.1. Company Overview
           13.2. Product Portfolio
           13.3. SWOT Analysis
           13.4. Financial Overview
           13.5. Strategic Overview
        14. Influvac
           14.1. Company Overview
           14.2. Product Portfolio
           14.3. SWOT Analysis
           14.4. Financial Overview
           14.5. Strategic Overview
        15. Biological
           15.1. Company Overview
           15.2. Product Portfolio
           15.3. SWOT Analysis
           15.4. Financial Overview
           15.5. Strategic Overview
        16. PaxVax Corporation
           16.1. Company Overview
           16.2. Product Portfolio
           16.3. SWOT Analysis
           16.4. Financial Overview
           16.5. Strategic Overview
        17. Emergent BioSolutions Inc
           17.1. Company Overview
           17.2. Product Portfolio
           17.3. SWOT Analysis
           17.4. Financial Overview
           17.5. Strategic Overview
        18. CNBG
           18.1. Company Overview
           18.2. Product Portfolio
           18.3. SWOT Analysis
           18.4. Financial Overview
           18.5. Strategic Overview
        19. Takeda Pharmaceutical Co. Ltd.
           19.1. Company Overview
           19.2. Product Portfolio
           19.3. SWOT Analysis
           19.4. Financial Overview
           19.5. Strategic Overview
        20. NPS MedicineWise.
           20.1. Company Overview
           20.2. Product Portfolio
           20.3. SWOT Analysis
           20.4. Financial Overview
           20.5. Strategic Overview

  • 18.  Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated
      by administrations
        5. The overall economic slowdown of the developing and developed nations

  • 19.  FutureWise SME Key Takeaway Points for Client
    •   

Partner

Our Clients